Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.51 |
| ▸ | MAP2K2 | P36507 | 13/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929737 | 0.88 | MAP2K1 (0.45) | MAP2K1MAP2K2PIM1CAMK2BIDO1 | |
| SCHEMBL391717 | 0.88 | MAP2K1 (0.48) | MAP2K1MAP2K2PIM1CAMK2BIDO1 | |
| SCHEMBL390166 | 0.86 | MAP2K1 (0.46) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL346016 | 0.85 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL1681646 | 0.85 | MAP2K1 (0.49) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 | |
| SCHEMBL1681534 | 0.83 | MAP2K1 (0.42) | MAP2K1MAP2K2 | |
| SCHEMBL15826953 | 0.83 | KMT2A (0.40) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL1681152 | 0.83 | MAPT (0.38) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL3691221 | 0.81 | MAP2K1 (0.48) | MAP2K1MAP2K2PIM1CAMK2BIDO1 | |
| SCHEMBL390986 | 0.81 | MAP2K1 (0.58) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-9174933-B2 | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174933-B2 | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2009018233-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1912636-A2 | N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK | Ardea Biosciences, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2007121269-A2 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007014011-A2 | N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | MAP2K1 32/4885MAP2K2 23/4885PIM1 67/4885 |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | MYLK2, MAPK1, MAP3K1 | MAP2K1 100/4885MAP2K2 80/4885PIM1 172/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K1 52/4885MAP2K2 48/4885PIM1 66/4885 |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | NRAS, BRAF, HRAS | MAP2K1 49/4885MAP2K2 42/4885PIM1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.